Bayer Agrees to $7.25 Billion Settlement Over Roundup Cancer Lawsuits

The proposed settlement aims to resolve thousands of U.S. lawsuits alleging Bayer failed to warn of Roundup's cancer risks.

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Agrochemical company Bayer has announced a proposed $7.25 billion settlement to resolve thousands of U.S. lawsuits alleging its popular weedkiller Roundup caused cancer. The settlement comes as the U.S. Supreme Court prepares to hear arguments on Bayer's assertion that the EPA's approval of Roundup without a cancer warning should invalidate state court claims. The proposed settlement would eliminate some of the risk from the Supreme Court ruling, both for Bayer and for patients seeking damages.

Why it matters

The Roundup cancer lawsuits have plagued Bayer since it acquired Monsanto in 2018. This proposed settlement represents a major step toward resolving the litigation uncertainty that has threatened Bayer's ability to continue selling Roundup in the U.S. agricultural market.

The details

Under the proposed $7.25 billion settlement, Bayer would resolve thousands of U.S. lawsuits alleging Roundup's key ingredient, glyphosate, can cause non-Hodgkin's lymphoma. Bayer disputes this cancer link but says mounting legal costs are threatening its Roundup business. The settlement still needs court approval and would not affect Bayer's separate Supreme Court case arguing the EPA's approval of Roundup should invalidate state court claims.

  • The proposed settlement was filed in St. Louis Circuit Court in Missouri on February 17, 2026.
  • The U.S. Supreme Court is preparing to hear arguments on Bayer's EPA approval case.

The players

Bayer

A Germany-based agrochemical company that acquired Roundup maker Monsanto in 2018.

Bill Anderson

Bayer's CEO, who stated the settlement gives the company a 'road to closure' on the Roundup litigation.

Got photos? Submit your photos here. ›

What they’re saying

“Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure.”

— Bill Anderson, CEO, Bayer (latimes.com)

What’s next

The proposed $7.25 billion settlement still needs approval from the St. Louis Circuit Court in Missouri.

The takeaway

This settlement represents a major development in Bayer's efforts to resolve the ongoing legal battles over Roundup's alleged cancer risks. While the company maintains Roundup is safe, the mounting litigation costs have threatened its ability to continue selling the popular weedkiller in the U.S. market.